What is the projected market valuation of the Canine Arthritis Treatment Market by 2035?

The projected market valuation for the Canine Arthritis Treatment Market is expected to reach 4.31 USD Billion by 2035. Read More

What was the market valuation of the Canine Arthritis Treatment Market in 2024?

The overall market valuation of the Canine Arthritis Treatment Market was 2.404 USD Billion in 2024. Read More

What is the expected CAGR for the Canine Arthritis Treatment Market during the forecast period 2025 - 2035?

The expected CAGR for the Canine Arthritis Treatment Market during the forecast period 2025 - 2035 is 5.45%. Read More

Which type of arthritis treatment segment is projected to have the highest valuation by 2035?

The Osteoarthritis treatment segment is projected to reach 2.2 USD Billion by 2035, indicating the highest valuation among arthritis types. Read More

What are the leading medication types in the Canine Arthritis Treatment Market?

The leading medication types include Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Disease-Modifying Anti-Rheumatic Drugs (DMARDs), with projected valuations of 1.73 USD Billion and 0.87 USD Billion respectively by 2035. Read More

Which companies are key players in the Canine Arthritis Treatment Market?

Key players in the Canine Arthritis Treatment Market include Zoetis, Boehringer Ingelheim, Elanco Animal Health, and Merck Animal Health. Read More

What is the projected valuation for nutritional supplements in the Canine Arthritis Treatment Market by 2035?

The projected valuation for nutritional supplements in the Canine Arthritis Treatment Market is expected to reach 0.87 USD Billion by 2035. Read More

How does the market for injectable treatments compare to oral treatments in 2035?

By 2035, the market for injectable treatments is projected to reach 1.29 USD Billion, while oral treatments are expected to reach 1.73 USD Billion. Read More

What is the expected market size for canine arthritis treatments targeting cats by 2035?

The expected market size for canine arthritis treatments targeting cats is projected to reach 1.5 USD Billion by 2035. Read More

What trends are influencing the growth of the Canine Arthritis Treatment Market?

Trends influencing growth include increasing awareness of canine arthritis and advancements in treatment options, contributing to a projected market expansion. Read More

Canine Arthritis Treatment Market

ID: MRFR/HC/39364-HCR

128 Pages

Rahul Gotadki

Last Updated: April 24, 2026

Canine Arthritis Treatment Market Research Report By Type of Arthritis (Osteoarthritis, Rheumatoid Arthritis, Other Types), By Medication Type (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Immunosuppressants, Nutritional Supplements, Pain Relievers), By Mode of Administration (Oral, Injectable, Transdermal, Topical), By Target Patient Type (Dogs, Cats, Other Animals) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Canine Arthritis Treatment Market Infographic

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1.1 EXECUTIVE SUMMARY
1.1.1 Market Overview
1.1.2 Key Findings
1.1.3 Market Segmentation
1.1.4 Competitive Landscape
1.1.5 Challenges and Opportunities
1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2.1 MARKET INTRODUCTION
2.1.1 Definition
2.1.2 Scope of the study
2.1.2.1 Research Objective
2.1.2.2 Assumption
2.1.2.3 Limitations
2.2 RESEARCH METHODOLOGY
2.2.1 Overview
2.2.2 Data Mining
2.2.3 Secondary Research
2.2.4 Primary Research
2.2.4.1 Primary Interviews and Information Gathering Process
2.2.4.2 Breakdown of Primary Respondents
2.2.5 Forecasting Model
2.2.6 Market Size Estimation
2.2.6.1 Bottom-Up Approach
2.2.6.2 Top-Down Approach
2.2.7 Data Triangulation
2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
3.1 MARKET DYNAMICS
3.1.1 Overview
3.1.2 Drivers
3.1.3 Restraints
3.1.4 Opportunities
3.2 MARKET FACTOR ANALYSIS
3.2.1 Value chain Analysis
3.2.2 Porter's Five Forces Analysis
3.2.2.1 Bargaining Power of Suppliers
3.2.2.2 Bargaining Power of Buyers
3.2.2.3 Threat of New Entrants
3.2.2.4 Threat of Substitutes
3.2.2.5 Intensity of Rivalry
3.2.3 COVID-19 Impact Analysis
3.2.3.1 Market Impact Analysis
3.2.3.2 Regional Impact
3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
4.1 Healthcare, BY Type of Arthritis (USD Billion)
4.1.1 Osteoarthritis
4.1.2 Rheumatoid Arthritis
4.1.3 Other Types
4.2 Healthcare, BY Medication Type (USD Billion)
4.2.1 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
4.2.2 Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
4.2.3 Immunosuppressants
4.2.4 Nutritional Supplements
4.2.5 Pain Relievers
4.3 Healthcare, BY Mode of Administration (USD Billion)
4.3.1 Oral
4.3.2 Injectable
4.3.3 Transdermal
4.3.4 Topical
4.4 Healthcare, BY Target Patient Type (USD Billion)
4.4.1 Dogs
4.4.2 Cats
4.4.3 Other Animals
4.5 Healthcare, BY Region (USD Billion)
4.5.1 North America
4.5.1.1 US
4.5.1.2 Canada
4.5.2 Europe
4.5.2.1 Germany
4.5.2.2 UK
4.5.2.3 France
4.5.2.4 Russia
4.5.2.5 Italy
4.5.2.6 Spain
4.5.2.7 Rest of Europe
4.5.3 APAC
4.5.3.1 China
4.5.3.2 India
4.5.3.3 Japan
4.5.3.4 South Korea
4.5.3.5 Malaysia
4.5.3.6 Thailand
4.5.3.7 Indonesia
4.5.3.8 Rest of APAC
4.5.4 South America
4.5.4.1 Brazil
4.5.4.2 Mexico
4.5.4.3 Argentina
4.5.4.4 Rest of South America
4.5.5 MEA
4.5.5.1 GCC Countries
4.5.5.2 South Africa
4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
5.1 Competitive Landscape
5.1.1 Overview
5.1.2 Competitive Analysis
5.1.3 Market share Analysis
5.1.4 Major Growth Strategy in the Healthcare
5.1.5 Competitive Benchmarking
5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
5.1.7 Key developments and growth strategies
5.1.7.1 New Product Launch/Service Deployment
5.1.7.2 Merger & Acquisitions
5.1.7.3 Joint Ventures
5.1.8 Major Players Financial Matrix
5.1.8.1 Sales and Operating Income
5.1.8.2 Major Players R&D Expenditure. 2023
5.2 Company Profiles
5.2.1 Zoetis (US)
5.2.1.1 Financial Overview
5.2.1.2 Products Offered
5.2.1.3 Key Developments
5.2.1.4 SWOT Analysis
5.2.1.5 Key Strategies
5.2.2 Boehringer Ingelheim (DE)
5.2.2.1 Financial Overview
5.2.2.2 Products Offered
5.2.2.3 Key Developments
5.2.2.4 SWOT Analysis
5.2.2.5 Key Strategies
5.2.3 Elanco Animal Health (US)
5.2.3.1 Financial Overview
5.2.3.2 Products Offered
5.2.3.3 Key Developments
5.2.3.4 SWOT Analysis
5.2.3.5 Key Strategies
5.2.4 Merck Animal Health (US)
5.2.4.1 Financial Overview
5.2.4.2 Products Offered
5.2.4.3 Key Developments
5.2.4.4 SWOT Analysis
5.2.4.5 Key Strategies
5.2.5 Vetoquinol (FR)
5.2.5.1 Financial Overview
5.2.5.2 Products Offered
5.2.5.3 Key Developments
5.2.5.4 SWOT Analysis
5.2.5.5 Key Strategies
5.2.6 Ceva Santé Animale (FR)
5.2.6.1 Financial Overview
5.2.6.2 Products Offered
5.2.6.3 Key Developments
5.2.6.4 SWOT Analysis
5.2.6.5 Key Strategies
5.2.7 PetIQ (US)
5.2.7.1 Financial Overview
5.2.7.2 Products Offered
5.2.7.3 Key Developments
5.2.7.4 SWOT Analysis
5.2.7.5 Key Strategies
5.2.8 Dechra Pharmaceuticals (GB)
5.2.8.1 Financial Overview
5.2.8.2 Products Offered
5.2.8.3 Key Developments
5.2.8.4 SWOT Analysis
5.2.8.5 Key Strategies
5.2.9 Virbac (FR)
5.2.9.1 Financial Overview
5.2.9.2 Products Offered
5.2.9.3 Key Developments
5.2.9.4 SWOT Analysis
5.2.9.5 Key Strategies
5.3 Appendix
5.3.1 References
5.3.2 Related Reports
6 LIST OF FIGURES
6.1 MARKET SYNOPSIS
6.2 NORTH AMERICA MARKET ANALYSIS
6.3 US MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.4 US MARKET ANALYSIS BY MEDICATION TYPE
6.5 US MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.6 US MARKET ANALYSIS BY TARGET PATIENT TYPE
6.7 CANADA MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.8 CANADA MARKET ANALYSIS BY MEDICATION TYPE
6.9 CANADA MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.10 CANADA MARKET ANALYSIS BY TARGET PATIENT TYPE
6.11 EUROPE MARKET ANALYSIS
6.12 GERMANY MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.13 GERMANY MARKET ANALYSIS BY MEDICATION TYPE
6.14 GERMANY MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.15 GERMANY MARKET ANALYSIS BY TARGET PATIENT TYPE
6.16 UK MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.17 UK MARKET ANALYSIS BY MEDICATION TYPE
6.18 UK MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.19 UK MARKET ANALYSIS BY TARGET PATIENT TYPE
6.20 FRANCE MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.21 FRANCE MARKET ANALYSIS BY MEDICATION TYPE
6.22 FRANCE MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.23 FRANCE MARKET ANALYSIS BY TARGET PATIENT TYPE
6.24 RUSSIA MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.25 RUSSIA MARKET ANALYSIS BY MEDICATION TYPE
6.26 RUSSIA MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.27 RUSSIA MARKET ANALYSIS BY TARGET PATIENT TYPE
6.28 ITALY MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.29 ITALY MARKET ANALYSIS BY MEDICATION TYPE
6.30 ITALY MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.31 ITALY MARKET ANALYSIS BY TARGET PATIENT TYPE
6.32 SPAIN MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.33 SPAIN MARKET ANALYSIS BY MEDICATION TYPE
6.34 SPAIN MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.35 SPAIN MARKET ANALYSIS BY TARGET PATIENT TYPE
6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.37 REST OF EUROPE MARKET ANALYSIS BY MEDICATION TYPE
6.38 REST OF EUROPE MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.39 REST OF EUROPE MARKET ANALYSIS BY TARGET PATIENT TYPE
6.40 APAC MARKET ANALYSIS
6.41 CHINA MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.42 CHINA MARKET ANALYSIS BY MEDICATION TYPE
6.43 CHINA MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.44 CHINA MARKET ANALYSIS BY TARGET PATIENT TYPE
6.45 INDIA MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.46 INDIA MARKET ANALYSIS BY MEDICATION TYPE
6.47 INDIA MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.48 INDIA MARKET ANALYSIS BY TARGET PATIENT TYPE
6.49 JAPAN MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.50 JAPAN MARKET ANALYSIS BY MEDICATION TYPE
6.51 JAPAN MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.52 JAPAN MARKET ANALYSIS BY TARGET PATIENT TYPE
6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.54 SOUTH KOREA MARKET ANALYSIS BY MEDICATION TYPE
6.55 SOUTH KOREA MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.56 SOUTH KOREA MARKET ANALYSIS BY TARGET PATIENT TYPE
6.57 MALAYSIA MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.58 MALAYSIA MARKET ANALYSIS BY MEDICATION TYPE
6.59 MALAYSIA MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.60 MALAYSIA MARKET ANALYSIS BY TARGET PATIENT TYPE
6.61 THAILAND MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.62 THAILAND MARKET ANALYSIS BY MEDICATION TYPE
6.63 THAILAND MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.64 THAILAND MARKET ANALYSIS BY TARGET PATIENT TYPE
6.65 INDONESIA MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.66 INDONESIA MARKET ANALYSIS BY MEDICATION TYPE
6.67 INDONESIA MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.68 INDONESIA MARKET ANALYSIS BY TARGET PATIENT TYPE
6.69 REST OF APAC MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.70 REST OF APAC MARKET ANALYSIS BY MEDICATION TYPE
6.71 REST OF APAC MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.72 REST OF APAC MARKET ANALYSIS BY TARGET PATIENT TYPE
6.73 SOUTH AMERICA MARKET ANALYSIS
6.74 BRAZIL MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.75 BRAZIL MARKET ANALYSIS BY MEDICATION TYPE
6.76 BRAZIL MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.77 BRAZIL MARKET ANALYSIS BY TARGET PATIENT TYPE
6.78 MEXICO MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.79 MEXICO MARKET ANALYSIS BY MEDICATION TYPE
6.80 MEXICO MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.81 MEXICO MARKET ANALYSIS BY TARGET PATIENT TYPE
6.82 ARGENTINA MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.83 ARGENTINA MARKET ANALYSIS BY MEDICATION TYPE
6.84 ARGENTINA MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.85 ARGENTINA MARKET ANALYSIS BY TARGET PATIENT TYPE
6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY MEDICATION TYPE
6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGET PATIENT TYPE
6.90 MEA MARKET ANALYSIS
6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.92 GCC COUNTRIES MARKET ANALYSIS BY MEDICATION TYPE
6.93 GCC COUNTRIES MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.94 GCC COUNTRIES MARKET ANALYSIS BY TARGET PATIENT TYPE
6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.96 SOUTH AFRICA MARKET ANALYSIS BY MEDICATION TYPE
6.97 SOUTH AFRICA MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.98 SOUTH AFRICA MARKET ANALYSIS BY TARGET PATIENT TYPE
6.99 REST OF MEA MARKET ANALYSIS BY TYPE OF ARTHRITIS
6.100 REST OF MEA MARKET ANALYSIS BY MEDICATION TYPE
6.101 REST OF MEA MARKET ANALYSIS BY MODE OF ADMINISTRATION
6.102 REST OF MEA MARKET ANALYSIS BY TARGET PATIENT TYPE
6.103 KEY BUYING CRITERIA OF HEALTHCARE
6.104 RESEARCH PROCESS OF MRFR
6.105 DRO ANALYSIS OF HEALTHCARE
6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
6.109 HEALTHCARE, BY TYPE OF ARTHRITIS, 2024 (% SHARE)
6.110 HEALTHCARE, BY TYPE OF ARTHRITIS, 2024 TO 2035 (USD Billion)
6.111 HEALTHCARE, BY MEDICATION TYPE, 2024 (% SHARE)
6.112 HEALTHCARE, BY MEDICATION TYPE, 2024 TO 2035 (USD Billion)
6.113 HEALTHCARE, BY MODE OF ADMINISTRATION, 2024 (% SHARE)
6.114 HEALTHCARE, BY MODE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
6.115 HEALTHCARE, BY TARGET PATIENT TYPE, 2024 (% SHARE)
6.116 HEALTHCARE, BY TARGET PATIENT TYPE, 2024 TO 2035 (USD Billion)
6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
7.1 LIST OF ASSUMPTIONS
7.1.1
7.2 North America MARKET SIZE ESTIMATES; FORECAST
7.2.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.2.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.2.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.2.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.3 US MARKET SIZE ESTIMATES; FORECAST
7.3.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.3.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.3.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.3.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.4 Canada MARKET SIZE ESTIMATES; FORECAST
7.4.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.4.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.4.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.4.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.5 Europe MARKET SIZE ESTIMATES; FORECAST
7.5.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.5.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.5.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.5.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.6 Germany MARKET SIZE ESTIMATES; FORECAST
7.6.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.6.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.6.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.6.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.7 UK MARKET SIZE ESTIMATES; FORECAST
7.7.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.7.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.7.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.7.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.8 France MARKET SIZE ESTIMATES; FORECAST
7.8.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.8.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.8.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.8.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.9 Russia MARKET SIZE ESTIMATES; FORECAST
7.9.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.9.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.9.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.9.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.10 Italy MARKET SIZE ESTIMATES; FORECAST
7.10.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.10.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.10.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.10.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.11 Spain MARKET SIZE ESTIMATES; FORECAST
7.11.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.11.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.11.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.11.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
7.12.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.12.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.12.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.12.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.13 APAC MARKET SIZE ESTIMATES; FORECAST
7.13.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.13.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.13.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.13.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.14 China MARKET SIZE ESTIMATES; FORECAST
7.14.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.14.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.14.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.14.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.15 India MARKET SIZE ESTIMATES; FORECAST
7.15.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.15.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.15.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.15.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.16 Japan MARKET SIZE ESTIMATES; FORECAST
7.16.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.16.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.16.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.16.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
7.17.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.17.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.17.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.17.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
7.18.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.18.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.18.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.18.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
7.19.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.19.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.19.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.19.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
7.20.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.20.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.20.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.20.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
7.21.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.21.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.21.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.21.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.22 South America MARKET SIZE ESTIMATES; FORECAST
7.22.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.22.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.22.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.22.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
7.23.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.23.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.23.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.23.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
7.24.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.24.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.24.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.24.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
7.25.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.25.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.25.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.25.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
7.26.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.26.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.26.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.26.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.27 MEA MARKET SIZE ESTIMATES; FORECAST
7.27.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.27.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.27.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.27.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
7.28.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.28.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.28.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.28.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
7.29.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.29.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.29.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.29.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
7.30.1 BY TYPE OF ARTHRITIS, 2025-2035 (USD Billion)
7.30.2 BY MEDICATION TYPE, 2025-2035 (USD Billion)
7.30.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Billion)
7.30.4 BY TARGET PATIENT TYPE, 2025-2035 (USD Billion)
7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Type of Arthritis (USD Billion, 2025-2035)

Osteoarthritis
Rheumatoid Arthritis
Other Types

Healthcare By Medication Type (USD Billion, 2025-2035)

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Immunosuppressants
Nutritional Supplements
Pain Relievers

Healthcare By Mode of Administration (USD Billion, 2025-2035)

Oral
Injectable
Transdermal
Topical

Healthcare By Target Patient Type (USD Billion, 2025-2035)

Dogs
Cats
Other Animals

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓